- Regulatory Status
- Other Names
- VEGFA165, MVCD1, VEGF, Vascular permeability factor (VPF)
- Ave. Rating
- Submit a Review
- Product Citations
VEGF (known also as VEGFA) was initially identified in conditioned medium from bovine pituitary follicular cells. VEGFA belongs to the VEGF family, which has the following members: VEGF-A, VEGF-B, VEGF-C (VEGF-2), VEGF-D, and PlGF (placental growth factor). In addition, viral VEGF homologs (collectively called VEGF-E) and snake venom VEGFs, such as T.f. (Trimeresurus flavoviridis) and svVEGF (called VEGF-F), have been described. VEGFA is alternatively spliced to generate variants with different numbers of amino acids, such as VEGFA121, VEGFA145, VEGFA165, and VEGFA189. VEGFA165 is predominant and responsible for VEGFA biological potency.
While VEGF121 is freely diffusible and does not bind to neuropilins (NRPs) or heparan sulphate (HS), VEGF165 and VEGF189 bind to both, resulting in retention on the cell surface or in the extracellular matrix. NRP1 lacks a typical kinase domain and acts as a co-receptor, and in response to VEGF165, NRP1 couples with VEGF-Rs to signal in endothelial cells. In addition, it has been suggested that bone marrow cells that are recruited to Ewing’s tumors are differentiated into vascular smooth muscle cells, and VEGF165 is responsible for this differentiation.
VEGFA is highly expressed in most of the solid tumors generated in breast, lung, renal, colorectal, and liver tissues. VEGFA has strong vascular permeability activity, and significantly contributes to the formation of ascites tumors. VEGFA can act as a direct proinflammatory mediator during the pathogenesis of rheumatoid arthritis (RA), and protect rheumatoid synoviocytes from apoptosis, which contributes to synovial hyperplasia. VEGFA is expressed in synovial macrophages and synovial fibroblasts in RA patients. Also, VEGFA is associated to age-related macular degeneration (AMD). AMD is due to neovascularization that originates from endothelial cells in the choroid that grow into neurosensory retina as choroidal neovascularization (CNV).
- Human VEGF-165, amino acids Ala27-Arg191 (Accession# AAM03108) was expressed in 293E cells.
- Molecular Mass
- The 165 amino acid recombinant protein has a predicted molecular mass of approximately 19 kD. The DTT-reduced protein migrates at approximately 20-28 kD and non-reduced protein migrates at 50 kD by SDS-PAGE. The N-terminal amino acid is Alanine.
- > 95%, as determined by Coomassie stained SDS-PAGE.
- 0.22 µm filtered protein solution in 5 mM citric acid, 5 mM NaHPO4, 0.15 M NaCl pH 4.0.
- Endotoxin Level
- Less than 0.01 ng per µg cytokine as determined by the LAL method.
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial (please contact technical support for concentration, or use our Lookup tool if you have a lot number.) Please note, new lots of the 100 µg size will be lot-specific and may differ from previous lots that had a fixed concentration.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
ED50 = 1 - 6 ng/ml, corresponding to a specific activity of 0.16 - 1.0 x 106 units/mg, as determined by the dose dependent stimulation of HUVEC cells proliferation.
The specific activity of recombinant human VEGF-165 is approximately 4.59 x 103 IU/µg when compared against the WHO Reference Reagent for Human VEGF-165 (NIBSC code: 88/646) as determined by the dose dependent stimulation of HUVEC cell proliferation.
For more information on specific activity, please visit the Recombinant Protein Unit Conversions page.
- Application Notes
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at firstname.lastname@example.org.
(PubMed link indicates BioLegend citation)
- Product Citations
VEGFA is a key player in vasculogenesis, the formation of blood vessels from progenitor cells, as well as angiogenesis. The expression of the VEGFA gene is upregulated via hypoxia, estrogen, and NF-κB pathways. In addition, VEGFA is upregulated by PDGF-BB, P1GF, TGFβ1, IGF1, FGFs, HGF, TNFα, and IL-1. VEGFA induces proliferation and cell migration in endothelial cells, and plays important roles during wound healing. Also, VEGFA regulates haematopoietic stem cell survival.
VEGFA interacts with vascular endothelial cells and monocytes/macrophages, which express VEGFR1. This interaction induces proliferation of endothelial cells and stimulates migration of monocytes/macrophages. VEGFR2 is expressed in endothelial cells and VEGFR2-signaling is essential for the development of vascular systems in the embryo.
- VEGFA binds and activates two tyrosine kinase receptors, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1)
- Cell Type
- Embryonic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells
- Biology Area
- Angiogenesis, Cell Biology, Neuroscience, Stem Cells, Synaptic Biology
- Molecular Family
- Cytokines/Chemokines, Growth Factors
- Antigen References
1. Conn G, et al. 1990. P. Natl. Acad. Sci. USA 87:1323.
2. Gerber H, et al. 2002. Nature 417:954.
3. Shibuya M, et al. 2006. J. Biochem. Mol. Biol. 39:469.
4. Reddy K, et al. 2008. Angiogenesis 11:257.
5. Shibuya M. 2008. BMB Rep. 41:278.
6. Monaghan-Benson E, et al. 2010. Am. J. Pathol. 177:2091.
7. Koch S and Claesson-Welsh L. 2012. Cold. Spring. Harb. Perspect. Med. 2:a006502.
- Gene ID
- 7422 View all products for this Gene ID
- View information about VEGF-A on UniProt.org
- Why choose BioLegend recombinant proteins?
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins.
- How does the activity of your recombinant proteins compare to competitors?
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
- Use formula Specific activity (Units/mg) = 10e6/ ED50 (ng/mL)